editor.ajphr@gmail.com
9409046853
e-ISSN: 2321-3647
logo

American Journal of Pharmacy and Health Research

Published

Emerging Drug Delivery Systems for Exemestane: Enhancing Therapeutic Outcomes in Breast Cancer

Published in August 2026 Issue 08 (Vol. 14, Issue 8, 2026)

Emerging Drug Delivery Systems for Exemestane: Enhancing Therapeutic Outcomes in Breast Cancer - Issue cover

Abstract

Breast cancer is a leading contributor of cancer-related death among women throughout the world. Exemestane (EXE), a third-generation irreversible aromatase inhibitor, is widely employed for the management of estrogen receptor-positive (ER+) breast cancer. Although the clinical efficacy of EXE is well established, poor aqueous solubility, low oral bioavailability, short plasma half-life, and low permeability limit its therapeutic efficacy. Therefore, the advancement of drug delivery technologies which can improve the pharmacokinetics profile, therapeutic efficacy, and tumor specific accumulation becomes important. In light of the above, the current review summarizes various formulation strategies of EXE including lipid-based nanoparticles, nanoemulsion, lipid nanocapsules, nanoparticles, liposomes, to name a few. However, polymeric mixed micelles are emerging as an effective nanocarrier system because they can improve drug solubilization, enhance cellular uptake, prolong systemic circulation, and facilitate passive tumor targeting. This review discusses the advantages and characterization techniques of polymeric micelles as a drug delivery system with special emphasis on methods of preparation, micellar architecture, and selection of polymers. Furthermore, the review explores polymeric micelles currently approved for clinical usage and undergoing clinical trials for an effective management of cancer. Additionally, incorporating micellar formulations into injectable hydrogels has gained popularity among the research community as it facilitates localised drug delivery and reduces the off target side effects thereby, improve the overall therapeutic efficacy. These advantages underscore the need for EXE encapsulated polymeric micelles integrated in situ hydrogel system to ensure sustained release and maintain therapeutic concentration of EXE to improve the breast cancer treatment. neena.pharma@gndu.ac.in

References

  1. [1]Singh G, Singh S, Singh A, Singh SK, Mehra A, Mahajan M, Singh AP, Bedi N. Chitosan Based Thermosensitive In Situ Hydrogel for Localized Delivery of Exemestane Loaded Micelles: A Novel Strategy for Enhanced Breast Cancer Therapy. J Pharm Innov 2026; 21(3): 314. Yaşar P, Ayaz G, User SD, Güpür G, Muyan M. Molecular mechanism of estrogen–estrogen receptor signaling. Reprod Med Biol 2017; 16(1): 4-20. Amaral C, Correia-da-Silva G, Almeida CF, Valente MJ, Varela C, Tavares-da-Silva E, Vinggaard AM, Teixeira N, Roleira FM. An exemestane derivative, oxymestane-D1, as a new multi-target steroidal aromatase inhibitor for estrogen receptor-positive (ER+) breast cancer: effects on sensitive and resistant cell lines. Molecules 2023; 28(2): 789. Zhu J, Lv L, Yan Y, Wang S, Lu X, Ma X, Sun X, Qin Y, Wu H, Yu G, Wang Q. Role of autophagy in tumorigenesis and drug resistance: molecular mechanisms and therapeutic targets. Mol Biomed 2026; 7(1): 28. Sarti S, Viansone AA, Serra O, Casadei C, Cecconetto L, Di Menna G, Farolfi A, Gianni C, Mariotti M, Merloni F, Palleschi M. Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions. Cancers 2025; 17(22): 3597. Talebibidhendi N, Pourmadadi M, Yazdian F, Rashedi H, Rahdar A, Ghotekar S. Advancements in Exemestane-Loaded Nanocarriers For Targeted Breast Cancer Therapy: A Comprehensive Review. BioNanoSci 2025; 15(4): 558. Carballo-Pedrares N, Giménez VM, Alonso MJ. Clinical translation of injectable hydrogels: from bioactive polymers to long-acting drug delivery systems. Drug Deliv Transl Res 2026; 22: 1-24. Agrawal A, Javanmardi Y, Watson SA, Serwinski B, Djordjevic B, Li W, Aref AR, Jenkins RW, Moeendarbary E. Mechanical signatures in cancer metastasis. NPJ Biol Phys Mech 2025; 2(1): 3. Liu Z, Chen J, Ren Y, Liu S, Ba Y, Zuo A, Luo P, Cheng Q, Xu H, Han X. Multi-stage mechanisms of tumor metastasis and therapeutic strategies. Signal Transduct Target Ther 2024; 9(1): 270. Bellanger M, Zeinomar N, Tehranifar P, Terry MB. Are global breast cancer incidence and mortality patterns related to country-specific economic development and prevention strategies. J Glob Oncol 2018; 4: 1-6. Al-Shami K, Awadi S, Khamees AA, Alsheikh AM, Al-Sharif S, Ala’Bereshy R, Al-Eitan SF, Banikhaled SH, Al-Qudimat AR, Al-Zoubi RM, Al Zoubi MS. Estrogens and the risk of breast cancer: A narrative review of literature. Heliyon 2023; 9(9). Swaminathan H, Saravanamurali K, Yadav SA. Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment. Oncol 2023; 40(8): 238. Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, Huang L, Liu CC, Shao ZM, Yu KD. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther 2025; 10(1): 49. Zheng L, Gökmen-Polar Y, Badve SS. Is conservative management of ductal carcinoma in situ risky. NPJ Breast Cancer 2022; 8(1): 55. McCart Reed AE, Kalinowski L, Simpson PT, Lakhani SR. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast Cancer Res 2021; 23(1): 6. Waghray D, Zhang Q. Inhibit or evade multidrug resistance P-Glycoprotein in cancer treatment : Miniperspective. J Med Chem 2017; 61(12): 5108–21. Odrobińska J, Neugebauer D. Micellar carriers based on amphiphilic PEG/PCL graft copolymers for delivery of active substances. Polymers 2020; 30 12(12): 2876. Wang X, Shen L, An Z. Dispersion polymerization in environmentally benign solvents via reversible deactivation radical polymerization. Prog Polym Sci 2018; 83: 1-27. Kotta S, Aldawsari HM, Badr-Eldin SM, Nair AB, Yt K. Progress in polymeric micelles for drug delivery applications. Pharmaceutics 2022; 14(8): 1636. Khaliq NU, Lee J, Kim S, Sung D, Kim H. Pluronic F-68 and F-127 based nanomedicines for advancing combination cancer therapy. Pharmaceutics 2023; 15: 1-25. Su K, Yang Y, Wu Q, Mao Y, Hu Y. Preparation of Polymeric Micelles of Curcumin with Pluronic P123 and Assessment of. Adv Pharmacoepidemiol Drug Saf 2016; 5(3). Negut I, Bita B. Polymeric micellar systems—a special emphasis on “smart” drug delivery. Pharmaceutics 2023; 15(3): 976. Narang AS, Delmarre D, Gao D. Stable drug encapsulation in micelles and microemulsions. Int J Pharm 2007; 345(1-2): 9-36. Li J, Wang Q, Xia G, Adilijiang N, Li Y, Hou Z, Fan Z, Li J. Recent advances in targeted drug delivery strategy for enhancing oncotherapy. Pharmaceutics 2023; 15(9): 2233. Taylor MJ, Tomlins P, Sahota TS. Thermoresponsive gels. Gels 2017;3(1): 4.

Authors (7)

Neena Bedi

Department of Pharmaceutical S...

View all publications →

Ashnoor Kaur

Department of Pharmaceutical S...

View all publications →

Prabha Kumari

Department of Pharmaceutical S...

View all publications →

Gurpreet Singh

Department of Pharmaceutical S...

View all publications →

Ashish Tangotra

Department of Pharmaceutical S...

View all publications →

Puneet Verma

Department of Pharmaceutical S...

View all publications →

Gurdeep Singh

Department of Pharmaceutical S...

View all publications →

Download Article

PDF

Best for printing and citation

File size: 0.7 MB
Format: PDF

Summarise this paper with AI:

Article Information

AJPHR8140005

AJPHR-01-000949

89-118

2026-08-07

JATS XML

Article Impact

Views:2,175
Downloads:2,153

How to Cite

Bedi & Kaur & Kumari & Singh & Tangotra & Verma & Singh (2026). Emerging Drug Delivery Systems for Exemestane: Enhancing Therapeutic Outcomes in Breast Cancer. American Journal of Pharmacy and Health Research, 14(8), 89-118. https://ajphr.com/articles/AJPHR8140005

Article Actions

Whatsapp